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Key points: 
 
• Inflammatory cytokines, in particular IL-1b are key mediators of gouty inflammation 
• Multiple regulatory pathways modulate the activity of the inflammasome and the release of 
IL1b 
• Diet influences hyperuricemia as well as the inflammatory state of macrophages in gout 
• The resolution of gouty inflammation is regulated 
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Abstract 
The acute symptoms of gout are triggered by the inflammatory response to MSU crystals, 
mediated principally by macrophages and neutrophils. Innate immune pathways are of key 
importance and in particular the activation of the NLRP3-inflammasome leading to release of 
IL-1b and other pro-inflammatory cytokines. This review will highlight recent advances in 
our understanding of both positive and negative regulatory pathways as well as the genetic 
and environmental factors that modulate the inflammatory response. Some of these pathways 
can be manipulated and open novel therapeutic opportunities for the treatment of the acute 
attack.    
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Introduction   
Gout has become the most common cause of inflammatory arthritis, and its epidemiology 
worldwide points to an increase in incidence and prevalence in both developed and developing 
countries 1. It is due to hyperuricemia (serum urate levels > 7mg/L [420 umol/L]  leading to 
formation and deposition of monosodium urate (MSU) crystals. Clinically, it is characterized by 
acute episodes of joint inflammation, usually affecting a single joint, interspersed by symptom free 
periods of variable duration. If untreated, it typically progresses to the formation of urate deposits 
(tophi) in soft tissues, recurrent attacks of arthritis affecting multiple joints and progressive joint 
destruction. Other complications include renal deposits of uric acid that can provoke renal failure 
and the formation of renal stones. These and other clinical features have been reviewed recently by 
Dalbeth 2.  
Gout is now regarded as a prototypical inflammatory disease driven by activation of the innate 
immune system and has also been termed an "autoinflammatory disease". However this 
classification is misleading, for unlike hereditary autoinflammatory disorders, the acute trigger of 
gout is MSU crystals. Uric acid itself is an endogenous and ubiquitous metabolite that is considered 
to possess little pro-inflammatory properties, and crystal formation is needed to provoke clinically 
observed inflammation.  
The study of the underlying mechanisms of gouty inflammation has given us remarkable insights 
into the control of the inflammasome and pro-inflammatory cytokine release. Nevertheless, we must 
bear in mind some of the other distinguishing features of gout: 1) the attack is usually self-limiting, 
and 2) that crystals can be present without an inflammatory response. These observations imply that 
there are regulatory mechanisms that modify the acute inflammatory response, and a thorough 
understanding of pro- as will as anti-inflammatory pathways may help to develop new strategies for 
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treatment. In this review we discuss the recent advances in the field of gout inflammation and new 
therapeutic strategies emerging to manage acute gout attacks. 
URIC ACID MEDIATED INFLAMMATION  
Activation of the NRLP3 Inflammasome by monosodium urate crystals 
MSU crystals trigger an inflammatory response from macrophages. The crystals are first taken up 
by macrophages and promote the assembly and activation of the NLRP3 inflammasome 4. 
Inflammasomes are cytosolic multiprotein complexes that can initiate inflammatory responses 5 6. 
Inflammasomes assemble when pattern-recognition receptors such as NLRP3 sense activating 
signals that reach the cytosol of the cell. This leads to the oligomerization of the pattern-recognition 
receptor and the recruitment to the complex of adaptor proteins and effector enzymes (Figure 1). 
NLRP3 inflammasomes are formed by the recruitment of the adaptor ASC and subsequent 
recruitment of caspase-1. Following initial oligomerization within the inflammasome, ASC can 
further auto-assemble into high molecular weight oligomers. This process, referred to as “prion-
like” polymerization, amplifies the signals and virtually engages all ASC molecules into one active 
cellular complex 7. Recruitment and oligomerization of caspase-1 by this structure leads to 
activation and proteolytic processing of its substrates.  
The cytokines IL-1b and IL-18 are cleaved and activated by caspase-1. In gout, inflammasome 
mediated IL-1β-release triggers an important inflammatory response, with vasodilatation and rapid 
recruitment of neutrophils to the site of crystal deposition, and thereby drives acute inflammatory 
episodes 8.  
Additional caspase-1 substrates such as Gasdermins are emerging as downstream effectors of 
inflammasome engagement 9. Gasdermins promote cell death upon inflammatory caspases 
activation 10, 11. Caspase-1 or caspase-11 cleave Gasdermin D (GSDMD) to release its N-terminal 
portion that then polymerizes at the plasma membrane forming cytotoxic pores. These pores alter 
cellular integrity and result in cells death by pyroptosis. Pyroptosis, also known as inflammatory 
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caspases-mediated cell death, differs from apoptotic caspases-mediated cell death in that it result 
into the release of cytosolic content of cells, including a plethora of proinflammatory mediators and 
danger signals. Pyroptosis can therefore amplify the inflammatory response and facilitate the 
release of cytokines including IL-1b. Whether this pathway contributes to inflammation in gout 
remains to be established.  
In addition to inflammatory caspases, other proteases can contribute to IL-1 maturation 12. In the 
absence of the inflammasome, neutrophils can process proIL-1β by the activity of neutrophil-
derived serine proteases such as proteinase-3 (PR3) elastase and cathepsin G 12, 13. Other serine 
proteases can also process IL-1β 14. Some metalloproteinases and granzyme A have also been 
proposed to trigger the proteolytic activation IL-1β 15 16. It is unclear whether these pathways 
function as an amplifier of the inflammatory reaction, for example in tissues with robust neutrophil 
recruitment, or function as backup mechanisms that maintain IL-1β production in condition where 
inflammasome proteins are absent or inhibited.  
Despite the fact that activation of IL-1β production and NLRP3 inflammasome's role in gout is well 
described, the upstream pathway that links monosodium urate crystals to NLRP3 activation are 
poorly understood. We can dissect inflammasome engagement into two prerequisite steps: priming 
and activation. Relying on two signals is a key feature of most inflammasomes and increases the 
specificity of the response and avoids inappropriate firing of the pathway. 
MECHANISMS OF INFLAMMATION: PRIMING  
Priming, also known as signal 117, controls the expression of all components required for the 
assembly and activation of the inflammasome and contribute to the expression of the precursor 
proteins that are substrate of inflammatory caspases. This inflammasome-competent stage is 
achieved as a result of an inflammatory milieu and can originate by the engagement of innate 
immune receptors such as Toll-like receptors (TLRs) or as part of an auto-amplification loop via IL-
1β itself.  
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Signalling pathways mediated by cell surface receptors coordinates the innate immune response. 
The best known are the TLR family of receptors, and in particular, TLR2 and TLR4 have been 
implicated in gouty inflammation. Earlier work showed that TLR2 and TLR4 deficient mice have 
an impaired neutrophil response to MSU in the air pouch model 18. A direct interaction between 
MSU crystals and the TLRs was postulated, as macrophages deficient for these receptors did not 
take up MSU crystals as efficiently as their wild type macrophages. Subsequent data suggest that 
TLRs regulate gouty inflammation by recognition of ligands that "prime" monocytes and 
macrophages to produce proIL-1β. MRP 8 and 14 are endogenous ligands of TLR4 and are secreted 
upon activation of phagocytes. Patients with gout and mice that are injected with MSU produced 
high levels of MRP 8 and 14, and genetic deletion of MRP 14 reduced the response to MSU in mice 
19. Another ligand that may play a role in macrophage priming in gout is free fatty acids. In a murine 
model of gout, arthritis was only observed when mice were injected with both C18 free fatty acids 
(FFA) and MSU crystals, and injection of MSU alone or C18 FFA alone was not sufficient to elicit 
inflammation. Furthermore, it was demonstrated that TLR2 is the receptor that mediated C18 FFA's 
effects on macrophages 20. The mechanisms of how TLRs can regulate inflammation have recently 
been reviewed 21. 
Other factors such as Granulocyte-macrophage colony-stimulating factor (GM-CSF) and the  
complement C5a have been proposed to affect priming in gout. In GM-CSF-neutralized mice, lower 
levels of IL-1β were observed following stimulation with MSU crystals. These monocytes also 
exhibited decreased expression of NLRP3 and proIL-1β 23. Similarly, treatment with C5a increased 
the expression of IL-1β and IL-18 and exacerbated MSU-mediated peritonitis in a mouse model of 
gout {An, 2014 #69;Khameneh, 2017 #68}.  
 
While priming is necessary for inflammasome assembly, this step is non-specific and can result 
from various conditions and signals that promote an underlining inflammatory response. It provides 
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an environment for inflammasome engagement, but it is not sufficient to trigger the inflammasome 
pathway per se.  
MECHANISMS OF INFLAMMATION: CATALYZING INFLAMMASOME ASSEMBLY  
A second signal (signal 2) is required for inflammasome activation. This signal is more specific 
than signal 1. It directly drives post-transcriptional and translational aggregation and polymerization 
of the inflammasome components. The mechanisms by which monosodium urate crystals trigger 
signal 2 to promote NLRP3 activation are still poorly understood. However several steps commonly 
found upstream of NLRP3 are involved. 
Perturbation of cellular ionic balances, in particular potassium efflux and calcium influx, is the first 
feature characteristic of NLRP3 inducers 24, 25. This ionic perturbation is necessary for mitochondrial 
reactive oxygen (ROS) generation upstream of NLRP3 inflammasome assembly. ROS production is 
also an essential step required for inflammasome formation, it is increased by MSU-mediated 
Leukotriene B4 {Amaral, 2012 #22} and may contribute to engage NEK7, a member of the family 
of mammalian NIMA-related kinases (NEK proteins). NEK7 directly binds NLRP3 and may be the 
common NLRP3 activating ligand 26-28. The important questions that remain to be resolved are how 
NEK7 interacts with NLRP3 and the mechanisms by which the crystals promote the ionic changes 
that ultimately engage the NLRP3 activating cascade.  
IL-1b IS A KEY CYTOKINE IN GOUT  
IL-1b is a cytokine that acts on multiple cell types to elicit inflammatory responses 29. It promotes 
vasodilatation leading to the recruitment of monocytes and neutrophils to sites of tissue insults, a 
response that is crucial in combating infection and restoring tissue homeostasis. However sustained 
IL-1b secretion can result in the production of matrix degrading enzymes that breaks down cartilage 
and bone30. At the systemic level, IL-1 elicits a fever response by acting directly on the 
hypothalamic temperature regulation centre 31.  
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IL-1β is mainly produced by innate immune cells and signals to target cells by binding to the IL1 
receptor type 1 (IL1R1). Once activated, IL1R1 and its co-receptor IL1 receptor accessory protein 
(IL1RAP) recruit a signalling complex that shares components with TLR signalling, leading to the 
activation of pro-inflammatory transcription factors including nuclear factor kB (NFkB), as well as 
p38, c-Jun N-terminal kinase (JNK) (Figure 2). These transcription factors in turn promote the 
transcriptional upregulation of chemokines and proinflammatory mediators that orchestrate the IL-
1-mediated inflammatory response. 
It is now widely accepted that IL-1b is a pivotal cytokine in acute gout 32, but a role for IL-1a cannot 
be ruled out. IL-1a is released during crystal-induced inflammation and mice with deletion of the 
IL-1Β gene are still capable of mounting a neutrophil response 33. The clinical relevance of IL-1 is 
supported by data from a number of different clinical studies of IL-1 inhibition 34. Although IL-1 
inhibition is not recommended as a first-line anti-inflammatory treatment, the results from clinical 
trials (of canakinumab) and cohort studies of patients who have received anakinra as treatment of 
acute flares showed a rapid onset of pain relief and it was observed that nearly all treated patients 
responded. Patients who had subsequent flares responded equally well when treated with again with 
canakinumab 35 and in our personal experience, anakinra was also effective when given for recurrent 
flares. The clinical experience with different IL-1 inhibitors in the treatment of gout is detailed in a 
later section. 
Other cytokines contributing to inflammation in Gout  
IL-8, also known as CXCL8 is a macrophage-secreted chemokine that acts principally on 
neutrophils. Recent data showed that it is significantly increased during an acute attack in three 
different cohorts of patients, and interesting, its levels remained high during the intercritical phase 
of gout and also in patients that had concomitant diabetes. In contrast, other co-morbidities that are 
commonly seen in gout (such as cardiovascular disease and chronic kidney disease) were not 
associated with high IL-8 levels 36. The mechanisms underlying these observations have not yet been 
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elucidated, but suggest that neutrophil recruitment and neutrophil activation are key inflammatory 
pathways. 
 
Soluble uric acid as a modulator of inflammation 
In gout, it is the formation of MSU crystals that trigger acute inflammation, but data show that 
hyperuricemia can modulate the inflammatory response. Hyperuricemia by itself, in the absence of 
crystals, is able to skew the leukocyte response towards a more inflammatory pattern through 
epigenetic modifications of histone methylation. In patients with hyperuricemia, this was shown by 
enhanced production of IL-1b and IL-6 and concomitant reduction of IL1RA release 39. 
INFLUENCE OF DIETARY FACTORS AND THE MICROBIOME ON GOUT 
INFLAMMATION 
Clinical observations indicate that dietary factors play a major role in gout, and the link between 
patterns of food consumption and hyperuricemia and gout has long been established 40. More 
recently, the role of particular foods in triggering an acute attack has been raised, and findings from 
an internet-based survey suggest that high purine content increases the risk of an acute attack of 
gout five-fold 41. However, the components of food and how they can lead to an attack remains to be 
identified. As mentioned earlier, long chain (C18) fatty acids may play a role in priming 
macrophages to release IL-1b when they phagocytose MSU crystals 20.   
Another mechanism that has been studied recently is the gut microbiome and its interaction with 
inflammatory cells and how this affects inflammation. Using a mouse model of gout, it was shown 
that germ-free mice showed attenuated MSU-induced inflammation and this effect was reproduced 
by antibiotic treatment. They went on to show that these effects were mediated by acetate, a short-
chain fatty acid that is released by gut bacteria. Acetate acts via the macrophage GPR-43 receptor to 
modulate inflammasome activation and IL-1b production. Restoring the normal gut flora in germ 
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free mice, and the addition of acetate restored the inflammatory properties 42. The same group 
further went on to show that a high fibre diet can attenuate arthritis in the same murine model of 
gout 43.  In that study it was proposed that increased production of acetate and other short chain fatty 
acids resulting from the high fibre diet, regulated resolution of inflammation possibly by impacting 
neutrophils 43. These studies suggest that environmental factors such as microbial metabolites can 
differentially regulate the cell types and pathways of gouty inflammation. The changes in the 
microbiome in gout patients have not been extensively studied. There is one report that found that 
gout patients had a different bacterial flora compared with control subjects and was similar to that 
found in diabetics 44. These findings need to be reproduced in larger cohorts before we can draw 
clear conclusions on how the microbiome modulates inflammation in gout. 
Although there is great interest in using diet to modulate hyperuricemia, its overall effect is modest. 
However, dietary factors may influence gouty inflammation. Recent clinical data suggest that 
higher dietary consumption of omega-3 fatty acids is associated with a lower frequency of acute 
gout flares 45. Experimentally,      -3 fatty acids (eicosapentaenoic acid and docosahexaenoic 
acid) can inhibit NLRP3 inflammasome activation via a pathway that involves the G-protein 
coupled receptors GPR120 and GPR40 and b-arrestin2 46. These findings require confirmation by 
intervention trials using omega-3 in gout. 
 
GENETICS OF GOUTY INFLAMMATION 
Genetic studies including genome-wide association studies (GWAS) have identified dozen 
susceptibility loci associated with hyperuricemia and gout 47. These loci mostly influence uric acid 
levels by affecting pathways such as renal and gut excretion of uric acid. While hyperuricemia may 
influence oxidative stress and thereby have some impact on inflammatory pathways, whether these 
polymorphisms may directly modulate inflammatory responses, beyond promoting uric acid 
crystallization, remain to be demonstrated.  
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Two studies demonstrated an association of gout with functional variants in CARD8 48, 49. CARD8 is 
a potential negative regulator of the NLRP3 inflammasome. It therefore possible that these 
polymorphisms may increase inflammasome activity and thereby contribute to the intensity or 
duration of NLRP3 engagement in gouty episodes.  In addition there is genetic evidence for a role 
of TLR4 in gout. Employing a candidate gene approach, two studies, one performed in Han Chinese 
and the other in patients with a European ancestry, found a significant association between the same 
genetic polymorphism of the TLR4 gene (rs2149356) with gout 50, 51.  These polymorphisms may 
impact the priming phase of inflammasome engagement or may have a broader impact on the 
inflammatory responses in these patients.  
One study linked gout incidence with a polymorphism within the gene Peroxisome proliferator-
activated receptor gamma coactivator 1-b (PPARGC1B) {Chang, 2017 #70}. It was shown that this 
variant increased NLRP3 and IL-1β expression. Because PPARGC1B function as a regulator of 
PPARg , a master regulator of metabolism, this genetic evidence may link metabolic deregulation 
with gouty inflammation.  
 
FACTORS CONTRIBUTING TO THE RESOLUTION OF INFLAMMATION  
Monocytes and macrophages are the major cellular sources of IL-1, but at the site of inflammation, 
neutrophils predominate. The major pro-inflammatory role of the neutrophil and the mechanisms of 
interaction between MSU crystals and the neutrophil has been reviewed 52. Interestingly, neutrophils 
also probably play a major role in the resolution of acute gout, by the formation of neutrophil 
extracellular traps (NET). This process is favoured by high neutrophil concentrations in the 
experimental setting (>10 x 106/ ml), and results in the formation of cellular aggregates that contain 
cellular debris, DNA as well as neutrophil proteases released into the NETs 53. NET formation is 
dependent on the generation of ROS and recent evidence also implicates molecules that regulate 
necroptosis via the RIPK3 pathway 54.  In the absence of RIPK3, NET formation was inhibited 
 13 
completely. Once formed, cellular aggregates containing NETs can degrade a wide range of 
inflammatory cytokines rapidly and in experimental models, inhibition of NET formation results in 
more severe and persistent gouty inflammation, whereas when NET formation is not impaired, there 
is a spontaneous resolution of joint inflammation after day 3 53.  These results show that neutrophils 
have a dual role in gouty inflammation: in the initial phase when inflammation is amplified by 
recruited neutrophils, as well as the resolution of inflammation (Figure 3). Currently, we do not 
have any therapies that can modulate this process.   
Anti-inflammatory cytokines also contribute to the resolution of the acute inflammatory process. In 
animal models, addition of exogenous TGFb1 reduced experimental inflammation 37; in man, 
TGFb1, IL-10 and IL1RA were elevated in synovial fluid and are associated with spontaneous 
resolution of gouty arthritis {Chen, 2011 #38}. Other factors may contribute to timely resolution of 
inflammation in gout. For example, the protein Annexin A1, a potential inhibitor of phospholipase 
A2 has been shown to decrease inflammation and promote resolution in mouse models of gout 
{Galvao, 2017 #67}.   
 
THERAPEUTIC STRATEGIES TARGETING INFLAMMATION PATHWAYS IN GOUT 
Treating gout requires two complementary approaches, one aimed at lowering uric acid level and 
the other to reduce inflammation. NSAIDs, colchicine and corticosteroids are commonly used and 
are effective in relieving pain and inflammation of the acute attack, however our recent insights into 
the biology of inflammation open the way to new therapeutic strategies (Figure 3). 
Modulators and inhibitors of the NLRP3 inflammasome  
As the NLRP3 inflammasome is a key pathway in the sensing of MSU crystals, strategies that 
impede its activation or affect its activity could reduce gouty inflammation. Interestingly, colchicine 
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blocks MSU crystals mediated NLRP3 activity in macrophages 32 probably by inhibiting 
microtubule-driven rearrangement of mitochondria following NLRP3 engagement with crystals 55.  
Other molecules that target key steps leading to NLRP3 assembly have been described to impact 
inflammation. The ketone bodies β-hydroxybutyrate suppresses inflammasome activation in 
response to monosodium urate crystals 56. These ketone bodies are produced in the liver of mammals 
during nutrient deprivation. Hence, starvation attenuated caspase-1 activation and IL-1β secretion in 
mouse models caloric restriction 56. Similarly, a ketogenic diet protected rats from urate crystals 
mediated gouty flares 57. Mechanistically, β-hydroxybutyrate has been proposed to inhibit potassium 
efflux upstream of NLRP3 and to directly impact inflammasome assembly 56. However a possible 
effect on priming has also been suggested 57. 
Multiple studies in gout have also shown beneficial effects of compounds that inhibit ROS 
production and decrease oxidative stress. Epigallocatechin gallate, a potent antioxidant polyphenol 
found in green tea has been shown to inhibit neutrophil infiltration and IL-1β secretion in a mouse 
model of monosodium urate crystal-mediated peritonitis 58. Morin, a natural flavonol, was found to 
impair monosodium urate crystal-induced inflammation in mouse macrophages 59. Rebamipide, a 
gastroprotective drug was shown to suppresses monosodium urate crystal-mediated Interleukin-1β 
activation and release in human THP-1 cells 60. Further studies are required to interrogate possible 
repositioning of this drug in gout. Xanthine oxidase inhibitors used in patients to decrease urate 
levels have also been shown to impact directly mitochondrial ROS production thereby inhibiting 
urate crystal mediated inflammasome activation 61. 
Inhibiting ROS production or potassium efflux are rather non-specific strategies that may have 
undesirable effects. Identification of more specific NLRP3 inhibitors could therefore present as 
more suitable therapeutics in gout. An example would be MCC950 (also known as CP-456,773  or 
CRID3) that has emerged as a potential drug of interest recently. This drug is a diarylsulfonylurea-
containing compound that was initially identified as an inhibitor of extracellular ATP-mediated 
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maturation of IL-1β 62.  This discovery preceded the initial description of the inflammasome and the 
identification of NLRP3 as the main sensor of extracellular ATP signals. More recently it was 
demonstrated that MCC950 specifically inhibit the NLRP3 inflammasome 63. It blocks NLRP3-
induced ASC oligomerization in mouse and human macrophages without affecting the activation of 
NLRP1, AIM2, or NLRC4 inflammasomes. Several NLRP3 activators, including monosodium 
urate crystals where inhibited by MCC950 63, 64, indicating that it may directly act on a conserved 
NLRP3 activating mechanism, However, exactly how this drug affects NLRP3 activation is not yet 
clear.  
Inhibitors of IL-1b maturation 
Considerable effort has been taken to develop specific caspase-1 inhibitors. VX-765, an orally 
available pro-drug, is the best studied. This drug is rapidly hydrolyzed by plasma and liver esterases 
into a potent and selective inhibitor of caspase-1 65. In animals, VX765 ameliorated the severity and 
progression of disease in a mouse model of collagen-induced arthritis 66. Caspase-1 inhibitors have 
also been shown to decrease IL-1b production and cartilage damage in a model of chronic 
destructive joint inflammation 67. However, its effects in gout have not been explored. Of particular 
importance will be the specificity of the inhibitor for caspase-1, as caspases share a very conserved 
catalytic core and off-target inhibition of apoptotic caspases may cause undesirable consequences.  
Based on studies that showed a role for serine proteases in proIL-1b             inhibitors 
of serine proteases could be of interest, either as monotherapy or in combination with caspase-1 
inhibitors in gout. Alpha-1-anti-trypsin (AAT) is a member of the serpin superfamily that inhibits 
many serine proteases. Recombinant human AAT-Fc fusion protein was found to be very effective 
in a mouse model of gouty arthritis 68. AAT can modulate inflammation at multiple levels and it is 
still unclear whether the effects observed in the gout model is directly caused by the inhibition of 
IL-1β processing. Yet theses data indicate that AAT-fc and possibly other serine protease inhibitors 
could be of therapeutics of interest for gout attacks.  
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IL-1 inhibitors 
The evidence for the clinical efficacy of IL-1 inhibition in acute gout has been recently reviewed 34. 
Two molecules are currently available, but only canakinumab has an indication for acute gout in the 
EU. The mechanism of action of the two drugs is different; canakinumab is a specific inhibitor of 
IL-1b, and anakinra inhibits both IL-1a and IL-1β binding to the IL1R1 receptor. Their properties 
are listed in table 1.  
IL-1 inhibition can relieve the acute symptoms of gout in patients who have not responded to 
conventional treatments or in whom the use of NSAIDs, colchicine or steroids are contraindicated. 
Its use in patients with severe renal and cardiac impairment, a clinical situation that commonly 
makes the choice of acute therapy difficult, has not been formally assessed in clinical trials, but in 
case series, no severe side effects have been reported 34. In the clinical trials involving canakinumab, 
a significant reduction of gout flares was seen for for up to 6 months, however the drug is not 
registered for this indication. As drugs have not been tested in large number of patients, their use is 
restricted to patients who have "difficult-to treat" disease and their safety in terms of infectious 
complications needs to be considered when they are prescribed. 
 
Future considerations 
Recent years have shown considerable progress in the understanding of the mechanisms of 
inflammation and the role of innate immune sensors in gout, however several question remain 
unanswered. Three questions are of particular interest. First the detailed specific mechanism by 
which NLRP3 is activated upon exposure to monosodium uric acid crystal is still unclear. Among 
the possibilities emerging is that NLRP3 may act as a guardian of cellular integrity that detects 
perturbations triggered when innate immune cells attempt at engulfing large particulates 69. This 
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would imply that the size and possibly the chemical nature and shape of those crystals may affects 
immune responses. Second, the caspase-1 independent mechanisms of IL-1 production, the 
proteases engaged and what trigger their activation are still poorly understood.  In this context it 
would be important to understand at what stage of the response these pathways contribute to the 
inflammatory phenotype and what are the cell types orchestrating this inflammasome-independent 
response. Finally, a key area of interest involves the mechanisms that initiate the gouty attacks, in 
patients that have persistent monosodium urate crystals deposits. It is still unclear whether specific 
initiation mechanisms contribute to triggering the inflammatory reaction, possibly by acting on 
priming signalling, or whether decrease in negative regulation of NLRP3 engagement are what 
promotes the inflammatory cascade. A better understanding of these questions may identify 
potential specific therapeutic strategies that will make the prevention and the management of gout 
more effective and specific. The study of this old disease provided us with a greater understanding 
of inflammatory pathways, solving the remaining questions still bears enormous potential for new 
discoveries of pathways and treatments that may impact several inflammatory diseases. 
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Figure legends  
Figure 1. NLRP3 inflammasome activation by monosodium urate crystals 
NLRP3 must be primed before activation. Priming (Signal 1) is mediated by an NF B–activating 
pathways, such as a member of the Toll-like receptors (TLRs). This signaling cascade induces the 
expression of functional inflammasome components such as NLRP3. Monosdium urate crystals 
provide signal 2 that triggers the assembly of the inflammasome.  The interaction of crystals with 
the plasma membrane promotes a cellular response that is still poorly understood but includes 
hallmarks of NLRP3 activation including potassium efflux through ion channels, and mitochondrial 
perturbations leading to the production and release of mitochondrial ROS into the cytosol. Then 
NLRP3 activating factors such as NEK7 are engaged promoting NLRP3 oligomerization and 
inflammasome assembly. The adaptor ASC is recruited to the inflammasome and nucleates into 
prion-like filaments. Caspase-1 is then recruited by ASC and oligomerizes off the ASC filaments 
leading to autoproteolytic activation of Caspase-1.  Active caspase-1 then promotes the proteolytic 
cleavage and maturation of proIL-1b into the biologically active IL-1b. Caspase-1 also promotes 
the cleavage of Gasdermin D (GSDMD) to generate an N-terminal cleavage product that 
oligiomerizes at the plasma membrane, causing the formation of pyroptotic pores. These pores 
disrupt the integrity of the cellular plasma membrane, and may contribute to the release of 
inflammatory mediators including IL-1b. 
Figure 2.  IL-1 signaling links inflammasome activation with the inflammatory cascades  
MSU crystals are detected by innate immune cells such as macrophages, monocytes or neutrophils 
that respond and produce active IL-1  IL-1β signals through the IL-1R complex, composed of the 
IL-1 receptor (IL-1R1) and its co-factor (IL-1RAcP), leading to recruitment of the adaptor MyD88. 
The expression of IL1R1 is widespread, present on leucocytes as well as endothelial and synovial 
cells. This results in the recruitment of effector proteins such as the IRAKs (mostly IRAK4) and 
TRAF6. This triggers the IKK complex and lead to the phosphorylation and degradation of the 
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inhibitor of NFkB, IkB   Activation of NF B, turns on the transcription of cytokines and 
neutrophil-recruiting chemokines, that will amplify the response and initiate a complex 
inflammatory cascade.  
Figure 3 Checks and balances of gouty inflammation 
Multiple regulatory pathways influence the acute inflammatory response to MSU. The interaction 
between macrophage and the neutrophil is important in the regulation of the acute inflammatory 
response. Modulators of NLRP3-inflammasome activation include acetate, omega-3 fatty acid and 
anti-oxidants can dampen IL-1β release. High concentration of neutrophils will also favor NETosis 
and the formation of NET aggregates, which contain proteases capable of degrading inflammatory 
cytokines. Finally, the release of TGFb by macrophages also acts as a brake on the inflammatory 
response.  
Figure 4 Therapeutic targets in gouty inflammation 
Pathways leading to IL-1 signaling can be inhibited at many different steps. Example of compounds 
and drugs that have been proposed to affect the various steps are shown.  While strategies that target 
potassium efflux or mitochondrial ROS are quite unspecific, inhibitors of NLRP3 assembly such as 
colchicine or inhibitors of IL-1b and IL-1R have already been proven effective in gout.  
  
Table 1: anti-IL-1 drugs  
Available IL-1 blockers  
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action 
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Molecular 
weight 
Administration 
anakinra IL-1 receptor 
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4-6 hours 17.3 kDa Subcutaneous 
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1 β 
monoclonal 
antibody 
26 days 145 kDa Subcutaneous 
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